Reports
Sale
Global Diabetic Neuropathy Market Size, Share, Forecast: By Type: Peripheral Neuropathy, Autonomic Neuropathy, Proximal Neuropathy, Focal Neuropathy; By Treatment Methods: Antidepressants, Anti-seizure Medications, Anticonvulsants, Others; By Distribution Channels; By End User; Regional Analysis; Supplier Landscape; 2023-2031
Global Diabetic Neuropathy Market Outlook
The global diabetic neuropathy market value was USD 4.74 billion in 2022, driven by the increasing prevalence of diabetic patients across the globe. The market size is anticipated to grow at a CAGR of 7.7% during the forecast period of 2023-2031 to achieve a value of USD 9.29 billion by 2031.
Diabetic Neuropathy Market: Introduction
Diabetic neuropathy is a condition that causes nerve damage in people with diabetes. Nerves are damaged by high blood sugar in diabetics, resulting in diabetic neuropathy. Legs and feet are the most severely affected body parts in this condition. There are also symptoms associated with neuropathy, such as pain and numbness, depending on the nerves affected, such as peripheral nerves, autonomic nerves, proximal nerves, and focal nerves. Following are the different types of diabetic neuropathy:
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
- Peripheral neuropathy affects the legs and feet.
- Autonomic neuropathy affects the digestive system, primarily the stomach.
- Proximal neuropathy affects buttocks and thighs.
Diabetes is a condition which needs to be treated at the earliest before it leads to severe consequences. It is not possible to cure neuropathic changes or provide pain relief with a single treatment. Various approaches are used to manage diabetic neuropathy, including intensive glucose control, treatment of risk factors, and treatment based on pathogenetic mechanisms.
The rapidly rising number of diabetic neuropathies and increased awareness in the next few years will compel major companies to launch new products. Thus, key players in the market are developing technologically advanced products to gain a competitive edge.
Global Diabetic Neuropathy Market Segmentations
The market can be segmented into categories like type, treatment methods, distribution channels, end user, and region.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Market Breakup by Type
- Peripheral Neuropathy
- Autonomic Neuropathy
- Proximal Neuropathy
- Focal Neuropathy
Market Breakup by Treatment Methods
- Antidepressants
- Anti-seizure Medications
- Anticonvulsants
- Electric Nerve Stimulation
- Topical Medications
- Others
Market Breakup by Distribution Channels
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacies
- Others
Market Breakup by End User
- Hospitals
- Research Institutes
- Specialty Clinics
Market Breakup by Region
- North America
- United States of America
- Canada
- Europe
- United Kingdom
- Germany
- France
- Italy
- Others
- Asia Pacific
- China
- Japan
- India
- ASEAN
- Australia
- Others
- Latin America
- Brazil
- Argentina
- Mexico
- Others
- Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Nigeria
- South Africa
- Others
Diabetic Neuropathy Market Scenario
The steep rise in diabetes cases will propel the growth of the market during the forecast period. The complications related to diabetes, cardiovascular diseases, obesity, and other complications related to glucose control contribute to neuropathy development. This includes the development of new products by manufacturers that are effective at treating neuropathy.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Additionally, increased urbanization is causing unhealthy lifestyles like unhealthy food consumption, sedentary living, and others that adversely affect the market growth. Other factors driving the growth of the diabetic neuropathy market include ageing population, growing health care facilities, and increasing health care costs.
Diabetic neuropathy drugs are becoming increasingly expensive, and alternative treatments for the condition are also available readily available. These factors are hindering the growth of the global market.
Availability of alternative treatments, such as radiotherapy and physical therapy, that may improve patient outcomes, is also obstructing the growth of the market. Other factors that could hamper the market growth include regulations, product recalls, and FDA approval delays.
Regional Outlook for the Diabetic Neuropathy Market
North America is leading the global market owing to the increasing prevalence of diabetes. Various factors contribute to the growth of the market, such as early adoption of drugs, availability of advanced therapies, and the availability of combination drugs.
It is also estimated that the Asia Pacific region is expected to grow at the fastest rate during the forecast period due to the high prevalence of diabetes, obesity, and cardiac arrhythmia-related issues, and government support for healthcare awareness and research activities.
Diabetic Neuropathy Market Therapeutic Landscape
People with diabetes can be affected by diabetic neuropathy, a chronic debilitating condition. The objective assessment of diabetic neuropathy makes it difficult to diagnose and evaluate in clinical trials. Currently, there is no treatment available to prevent or reverse neuropathy or to relieve pain completely.
Diabetic neuropathy could be treated with Nav 1.7 antagonists, calcium channel blockers, anti-NGF antibodies, and angiotensin II type 2 receptor antagonists.
As part of its neuropathic pain treatment program, Novartis AG introduced Tegerton (carbamazepine), a new epilepsy drug designed to reduce nerve impulses that cause pain in diabetics.
Nucynta ER, a pain reliever derived from opioids, used to treat diabetes-induced nerve damage, was also launched by Janssen Pharmaceuticals.
Among the recommended treatment options for diabetic neuropathy, there are antidepressants like amitriptyline and duloxetine as well as topical agents like gabapentin and pregabalin analogues and opioids for pain relief in neuropathy.
In order to alleviate pain and improve quality of life associated with diabetic neuropathy, more research is needed on the most effective drugs or combinations.
Clinical Trials
In current therapies, sensory deficits and aetiology are not addressed, so there is an unmet demand for treatment options that target the natural course of the condition.
The outcomes of recent randomized controlled trials show that some of these pathological treatments improve neuropathic endpoints clinically. Patients with neuropathic pain remain undertreated with effective analgesic monotherapy as limited number of patients able to achieve clinically meaningful results.
New pharmaceutical approaches have been expanded due to increased knowledge of neurobiology and phenotypic profiling of neuropathic pain.
A number of promising molecular structures are in clinical development, which will soon improve our therapeutic arsenal of diabetic neuropathy treatments.
In diabetic neuropathy, the disease progresses over time. Medication and lifestyle changes can alleviate this condition. Medications that control diabetes are the most effective in slowing the onset of complications caused by diabetes.
The FDA has approved these drugs for treating diabetic neuropathy:
- anticonvulsant Lyrica (pregabalin)
- antidepressant Cymbalta (duloxetine)
- opioid Nucinta (tapentadol)
Competitive Landscape
The report gives an in-depth analysis of the key players involved in the global diabetic neuropathy market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:
- NeuroMetrix, Inc
- Allergan PLC
- Pfizer, Inc
- Eli Lilly and Company
- Novartis AG
- Janssen Global Services, LLC
- Teva Pharmaceutical Industries Ltd.
- LUMITOS AG
- GSK plc
- Astellas Pharma Inc
- Glenmark Pharmaceuticals Ltd
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
|---|---|
| Base Year | 2022 |
| Historical Period | 2016-2022 |
| Forecast Period | 2023-2031 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Type |
|
| Breakup by Treatment Methods |
|
| Breakup by Distribution Channels |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Diabetes Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Diabetes Epidemiology Analysis
5.1 Epidemiology Overview (2016-2031)
5.2 North America Diabetes Epidemiology (2016-2031)
5.3 Europe Diabetes Epidemiology (2016-2031)
5.4 Asia Pacific Diabetes Epidemiology (2016-2031)
5.5 Latin America Diabetes Epidemiology (2016-2031)
5.6 Middle East and Africa Diabetes Epidemiology (2016-2031)
6 Global Diabetic Neuropathy Market Overview
6.1 Global Diabetic Neuropathy Market Historical Value (2016-2022)
6.2 Global Diabetic Neuropathy Market Forecast Value (2023-2031)
7 Global Diabetic Neuropathy Market Landscape
7.1 Diabetic Neuropathy: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Diabetic Neuropathy: Product Landscape
7.2.1 Analysis by Type
7.2.2 Analysis by Treatment Methods
7.2.3 Analysis by Distribution Channels
7.2.4 Analysis by End User
8 Diabetic Neuropathy Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Global Diabetic Neuropathy Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Global Diabetic Neuropathy Market Segmentation
11.1 Global Diabetic Neuropathy Market by Type
11.1.1 Market Overview
11.1.2 Peripheral Neuropathy
11.1.3 Autonomic Neuropathy
11.1.4 Proximal Neuropathy
11.1.5 Focal Neuropathy
11.2 Global Diabetic Neuropathy Market by Treatment Methods
11.2.1 Market Overview
11.2.2 Antidepressants
11.2.3 Anti-seizure Medications
11.2.4 Anticonvulsants
11.2.5 Electric Nerve Stimulation
11.2.6 Topical Medications
11.2.7 Others
11.3 Global Diabetic Neuropathy Market by Distribution Channels
11.3.1 Market Overview
11.3.2 Hospital Pharmacy
11.3.3 Retail Pharmacy
11.3.4 Online Pharmacies
11.3.5 Others
11.4 Global Diabetic Neuropathy Market by End User
11.4.1 Market Overview
11.4.2 Hospitals
11.4.3 Research Institutes
11.4.4 Specialty Clinics
11.5 Global Diabetic Neuropathy Market by Region
11.5.1 Market Overview
11.5.2 North America
11.5.3 Europe
11.5.4 Asia Pacific
11.5.5 Latin America
11.5.6 Middle East and Africa
12 North America Diabetic Neuropathy Market
12.1 Market Share by Country
12.2 United States of America
12.3 Canada
13 Europe Diabetic Neuropathy Market
13.1 Market Share by Country
13.2 United Kingdom
13.3 Germany
13.4 France
13.5 Italy
13.6 Others
14 Asia Pacific Diabetic Neuropathy Market
14.1 Market Share by Country
14.2 China
14.3 Japan
14.4 India
14.5 ASEAN
14.6 Australia
14.7 Others
15 Latin America Diabetic Neuropathy Market
15.1 Market Share by Country
15.2 Brazil
15.3 Argentina
15.4 Mexico
15.5 Others
16 Middle East and Africa Diabetic Neuropathy Market
16.1 Market Share by Country
16.2 Saudi Arabia
16.3 United Arab Emirates
16.4 Nigeria
16.5 South Africa
16.6 Others
17 Regulatory Framework
17.1 Regulatory Overview
17.1.1 US FDA
17.1.2 EU EMA
17.1.3 INDIA CDSCO
17.1.4 JAPAN PMDA
17.1.5 Others
18 Patent Analysis
18.1 Analysis by Type of Patent
18.2 Analysis by Publication year
18.3 Analysis by Issuing Authority
18.4 Analysis by Patent Age
18.5 Analysis by CPC Analysis
18.6 Analysis by Patent Valuation
18.7 Analysis by Key Players
19 Grants Analysis
19.1 Analysis by year
19.2 Analysis by Amount Awarded
19.3 Analysis by Issuing Authority
19.4 Analysis by Grant Application
19.5 Analysis by Funding Institute
19.6 Analysis by NIH Departments
19.7 Analysis by Recipient Organization
20 Clinical Trials Analysis
20.1 Analysis by Trial Registration Year
20.2 Analysis by Trial Status
20.3 Analysis by Trial Phase
20.4 Analysis by Therapeutic Area
20.5 Analysis by Geography
21 Funding and Investment Analysis
21.1 Analysis by Funding Instances
21.2 Analysis by Type of Funding
21.3 Analysis by Funding Amount
21.4 Analysis by Leading Players
21.5 Analysis by Leading Investors
21.6 Analysis by Geography
22 Partnership and Collaborations Analysis
22.1 Analysis by Partnership Instances
22.2 Analysis by Type of Partnership
22.3 Analysis by Leading Players
22.4 Analysis by Geography
23 Supplier Landscape
23.1 NeuroMetrix, Inc
23.1.1 Financial Analysis
23.1.2 Product Portfolio
23.1.3 Demographic Reach and Achievements
23.1.4 Mergers and Acquisitions
23.1.5 Certifications
23.2 Allergan PLC
23.2.1 Financial Analysis
23.2.2 Product Portfolio
23.2.3 Demographic Reach and Achievements
23.2.4 Mergers and Acquisitions
23.2.5 Certifications
23.3 Pfizer, Inc
23.3.1 Financial Analysis
23.3.2 Product Portfolio
23.3.3 Demographic Reach and Achievements
23.3.4 Mergers and Acquisitions
23.3.5 Certifications
23.4 Eli Lilly and Company
23.4.1 Financial Analysis
23.4.2 Product Portfolio
23.4.3 Demographic Reach and Achievements
23.4.4 Mergers and Acquisitions
23.4.5 Certifications
23.5 Novartis AG
23.5.1 Financial Analysis
23.5.2 Product Portfolio
23.5.3 Demographic Reach and Achievements
23.5.4 Mergers and Acquisitions
23.5.5 Certifications
23.6 Janssen Global Services, LLC
23.6.1 Financial Analysis
23.6.2 Product Portfolio
23.6.3 Demographic Reach and Achievements
23.6.4 Mergers and Acquisitions
23.6.5 Certifications
23.7 Teva Pharmaceutical Industries Ltd.
23.7.1 Financial Analysis
23.7.2 Product Portfolio
23.7.3 Demographic Reach and Achievements
23.7.4 Mergers and Acquisitions
23.7.5 Certifications
23.8 LUMITOS AG
23.8.1 Financial Analysis
23.8.2 Product Portfolio
23.8.3 Demographic Reach and Achievements
23.8.4 Mergers and Acquisitions
23.8.5 Certifications
23.9 GSK plc
23.9.1 Financial Analysis
23.9.2 Product Portfolio
23.9.3 Demographic Reach and Achievements
23.9.4 Mergers and Acquisitions
23.9.5 Certifications
23.10 Astellas Pharma Inc
23.10.1 Financial Analysis
23.10.2 Product Portfolio
23.10.3 Demographic Reach and Achievements
23.10.4 Mergers and Acquisitions
23.10.5 Certifications
23.11 Glenmark Pharmaceuticals Ltd
23.11.1 Financial Analysis
23.11.2 Product Portfolio
23.11.3 Demographic Reach and Achievements
23.11.4 Mergers and Acquisitions
23.11.5 Certifications
24 Diabetic Neuropathy - Distribution Model (Additional Insight)
24.1 Overview
24.2 Potential Distributors
24.3 Key Parameters for Distribution Partner Assessment
25 Key Opinion Leaders (KOL) Insights (Additional Insight)
26 Company Competitiveness Analysis (Additional Insight)
26.1 Very Small Companies
26.2 Small Companies
26.3 Mid-Sized Companies
26.4 Large Companies
26.5 Very Large Companies
27 Payment Methods (Additional Insight)
27.1 Government Funded
27.2 Private Insurance
27.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
In 2022, the global market of Diabetic Neuropathy attained a value of USD 4.74 billion.
The market is anticipated to grow at a CAGR of 7.7% during the forecast period of 2023-2031 to reach a value of USD 9.29 billion by 2031.
The rising cases of diabetes and launch of new products are the major factors driving the growth of the market.
North America has been leading the global market due to early adoption of drugs, availability of advanced therapies, and the availability of combination drugs.
The high cost of the product and the availability of alternatives for diabetic neuropathy are hindering the market growth.
Diabetes causes nerve damage, which is known as diabetic neuropathy. Diabetes-related high blood glucose levels, also known as blood sugar, and high levels of fats in the blood, such as triglycerides, can damage nerves over time.
The signs and symptoms of peripheral neuropathy include numbness, prickling, or tingling in your feet or hands that can spread up into your legs and arms. Sharp, jabbing, throbbing, or burning discomfort Touch sensitivity to the extreme.
The types of the condition include peripheral neuropathy, autonomic neuropathy, proximal neuropathy, and focal neuropathy.
The treatment methods include antidepressants, anti-seizure medications, anticonvulsants, electric nerve stimulation, and topical medications, among others.
The distribution channels in the market include hospital pharmacy, retail pharmacy, and online pharmacies, among others.
Purchase Options
Call us on
Purchase Full Report
Mini Report
$ 3499
$1999
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next UpdateSingle User License
$5999$2999-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next Update
Five User License
$7999$3999-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$9999$5999-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Contact AnalystAny Question? Speak With An Analyst
Request SampleView A Sample
Request CustomisationDid You Miss Anything, Ask Now
Why Expert Market Research?Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER